CN103415620B - 诱导针对EGFRvIII的免疫应答的方法和组合物 - Google Patents

诱导针对EGFRvIII的免疫应答的方法和组合物 Download PDF

Info

Publication number
CN103415620B
CN103415620B CN201180062129.XA CN201180062129A CN103415620B CN 103415620 B CN103415620 B CN 103415620B CN 201180062129 A CN201180062129 A CN 201180062129A CN 103415620 B CN103415620 B CN 103415620B
Authority
CN
China
Prior art keywords
sequence
egfrviii
polypeptide
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180062129.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103415620A (zh
Inventor
P·M·劳尔
K·巴哈贾特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Providence Health and Services Oregon
Chinook Therapeutics Inc
Original Assignee
Aduro Biotech Inc
Providence Health and Services Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc, Providence Health and Services Oregon filed Critical Aduro Biotech Inc
Publication of CN103415620A publication Critical patent/CN103415620A/zh
Application granted granted Critical
Publication of CN103415620B publication Critical patent/CN103415620B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180062129.XA 2010-11-17 2011-11-17 诱导针对EGFRvIII的免疫应答的方法和组合物 Expired - Fee Related CN103415620B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
US61/414,850 2010-11-17
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (2)

Publication Number Publication Date
CN103415620A CN103415620A (zh) 2013-11-27
CN103415620B true CN103415620B (zh) 2016-10-12

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180062129.XA Expired - Fee Related CN103415620B (zh) 2010-11-17 2011-11-17 诱导针对EGFRvIII的免疫应答的方法和组合物

Country Status (17)

Country Link
US (3) US9200057B2 (https=)
EP (1) EP2640842B1 (https=)
JP (1) JP5998370B2 (https=)
CN (1) CN103415620B (https=)
CA (1) CA2818353A1 (https=)
CY (1) CY1120622T1 (https=)
DK (1) DK2640842T3 (https=)
ES (1) ES2684684T3 (https=)
HR (1) HRP20181343T1 (https=)
HU (1) HUE039747T2 (https=)
LT (1) LT2640842T (https=)
PL (1) PL2640842T3 (https=)
PT (1) PT2640842T (https=)
RS (1) RS57630B1 (https=)
SI (1) SI2640842T1 (https=)
SM (1) SMT201800444T1 (https=)
WO (1) WO2012068360A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
KR20150084033A (ko) 2012-11-06 2015-07-21 아두로 바이오테크, 인코포레이티드 조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3134510B1 (en) * 2014-04-24 2023-11-01 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
CN107429289A (zh) * 2014-10-14 2017-12-01 宾夕法尼亚大学理事会 用于癌症治疗的联合疗法
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
CA2982543A1 (en) * 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
MX2017015149A (es) * 2015-05-26 2018-03-28 Advaxis Inc Inmunoterapia personalizada basada en vectores de suministro y usos de esta.
WO2016207859A1 (en) * 2015-06-24 2016-12-29 Advaxis, Inc. Manufacturing device and process for personalized delivery vector-based immunotherapy
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US10526609B2 (en) * 2016-08-01 2020-01-07 Aduro Biotech, Inc. Protein expression enhancer sequences and use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224868B1 (en) * 1994-11-28 2001-05-01 Thomas Jefferson University Reagent and processes for targeting mutant epidermal growth factor receptors
WO2009012488A1 (en) * 2007-07-19 2009-01-22 Duke University Assay for human anti-egrf variant iii antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法
EP2860253B1 (en) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
WO2010011870A2 (en) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions and methods for the treatment of hepatitis c
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
SMT201800444T1 (it) * 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224868B1 (en) * 1994-11-28 2001-05-01 Thomas Jefferson University Reagent and processes for targeting mutant epidermal growth factor receptors
WO2009012488A1 (en) * 2007-07-19 2009-01-22 Duke University Assay for human anti-egrf variant iii antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model;Michael J. Ciesielski，et al.;《Cancer Immunol Immunother》;20050228;第54卷(第2期);摘要，第108页左栏第1-2段和右栏第1-3段，图1以及第109页左栏第1段 *
Targeting of DEC-205 on human dendritic cells results in efficient MHC class;Katrin Birkholz，et al.;《BLOOD》;20100930;第116卷(第13期);第2277-2285页 *
Vaccination with minigenes encoding for novel ‘self’ antigens are effective in DNA-vaccination against neuroblastoma;N. Huebener，et al.;《Cancer Letters》;20030731;第197卷(第1-2期);摘要和第213页图1，第212页第1段 *

Also Published As

Publication number Publication date
JP5998370B2 (ja) 2016-09-28
CY1120622T1 (el) 2019-12-11
PT2640842T (pt) 2018-10-12
SMT201800444T1 (it) 2018-09-13
JP2014504851A (ja) 2014-02-27
PL2640842T3 (pl) 2018-11-30
EP2640842A1 (en) 2013-09-25
ES2684684T3 (es) 2018-10-04
SI2640842T1 (sl) 2018-09-28
EP2640842B1 (en) 2018-05-30
EP2640842A4 (en) 2014-04-09
US20180021420A1 (en) 2018-01-25
DK2640842T3 (en) 2018-08-13
RS57630B1 (sr) 2018-11-30
US9200057B2 (en) 2015-12-01
US9775891B2 (en) 2017-10-03
HUE039747T2 (hu) 2019-02-28
US20160074491A1 (en) 2016-03-17
US20140037662A1 (en) 2014-02-06
CN103415620A (zh) 2013-11-27
LT2640842T (lt) 2018-09-10
HRP20181343T1 (hr) 2018-10-19
WO2012068360A1 (en) 2012-05-24
CA2818353A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
CN103415620B (zh) 诱导针对EGFRvIII的免疫应答的方法和组合物
AU2017297610B2 (en) Compositions and methods for alphavirus vaccination
CN104955835B (zh) 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
US20120100170A1 (en) Compositions and methods for the treatment of hepatitis c
KR20110027695A (ko) Ｐｒｆａ＊ 돌연변이 리스테리아를 포함하는 조성물 및 그것의 사용방법
WO2008094188A2 (en) Methods and compositions using listeria for enhancing immunogenicity by prime boost
JP2015534822A (ja) 条件的弱毒化細菌種ならびにその調製法および使用法
TW201809274A (zh) 蛋白質表現強化子序列及其用途
HK1190757B (en) Methods and compositions for inducing an immune response to egfrviii
HK1190757A (en) Methods and compositions for inducing an immune response to egfrviii
US20130323275A1 (en) Methods and compositions for inducing a t-cell response to plasmodium species
WO2025119999A1 (en) Extracellular vesicle based vaccine platform
HK40006687A (zh) 蛋白质表达增强子序列及其用途
Moran Characterization of dendritic cells transduced with Venezuelan equine encephalitis virus replicon particles as therapeutic cancer vaccines
HK1215260B (zh) 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
HK1182137A (en) Methods and compositions using listeria for adjuvant treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1190757

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1190757

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161012

Termination date: 20201117